Kura Oncology announced the publication of preclinical findings for ziftomenib, a drug that received FDA approval in 2025.

The entities involved

• Kura Oncology →

  company in La Jolla, United States

  Nothing else this week.

• FDA →
  • Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
  • A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
• University of Michigan →

  public research university in Ann Arbor, Michigan

  • Activists in Michigan targeted organizations and pressured the University of Michigan over financial ties to Israel, using Hamas symbols in threats.Sun 20:32
  • Consumer Sentiment Index shows a disconnect from economic reality, leading critics to question the validity of the underlying economic data.Sat 11:37

Related events

• ADC Therapeutics is seeking accelerated approval from the FDA for its Zynlonta therapy.Jun 10
• Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.Aug 18
• OS Therapies, Inc. is seeking interim and final review data submissions from regulatory bodies while attending major global investment conferences.Sep 2
• Intellia Therapeutics is seeking FDA approval for its drug Lonvo-Z.Sep 8
• BioXcel Therapeutics received FDA approval for its drug and announced results from New Haven.Jun 7